Prestige Consumer Healthcare Expands OTC Portfolio with $1.045 Billion Brand Purchase

Prestige Consumer Healthcare spends $1.045 Billion on Breathe Right acquisition, adding $200 M revenue

• Deal valued at $1.045 billion, the largest in Prestige’s history.
• Acquired portfolio includes Breathe Right nasal strips and Dimetapp cough‑cold line.
• 2025 revenue forecast for the brands stands at about $200 million.
• Private‑equity sponsors Kelso & Co. and Juggernaut Capital Partners back the transaction.

How a $1 billion spend could reshape the over‑the‑counter market

MERGERS & ACQUISITIONS—Prestige Consumer Healthcare announced Friday that it will acquire a suite of over‑the‑counter (OTC) brands from Foundation Consumer Healthcare for $1.045 billion. The deal brings together two iconic products—Breathe Right nasal strips and Dimetapp cough‑cold relief—into Prestige’s growing portfolio of consumer‑health staples.

According to the company, the acquired brands generated roughly $200 million in revenue in 2025, implying a purchase multiple of just over five times annual sales. The transaction underscores the appetite of private‑equity‑backed firms to consolidate fragmented OTC assets and leverage scale for distribution efficiencies.

Industry observers note that the acquisition could accelerate Prestige’s push into the lucrative nasal‑care segment, a space traditionally dominated by a handful of large pharmaceutical players.

Strategic Rationale Behind the $1.045 Billion Deal

Prestige’s leadership framed the purchase as a “strategic expansion of our over‑the‑counter portfolio,” a statement that reflects a broader trend of consolidation in the consumer‑health sector. By adding Breathe Right—a brand with strong retail shelf presence—and Dimetapp, which enjoys seasonal demand spikes, Prestige aims to smooth revenue volatility and deepen its penetration across pharmacy, mass‑retail, and e‑commerce channels.

Private‑Equity Influence on Deal Structure

Kelso & Co. and Juggernaut Capital Partners, the private‑equity firms backing Prestige, have a track record of engineering growth through add‑on acquisitions. Kelso’s partner, Michael L. Saffran, told analysts in a recent conference call that “leveraging platform companies to acquire complementary brands is a proven pathway to value creation.” The $1.045 billion price tag, while sizable, aligns with the firms’ historical willingness to pay premium multiples for high‑visibility consumer brands.

Financial Implications and Synergy Outlook

Prestige disclosed that the acquired portfolio contributed about $200 million in 2025 revenue, translating to a 5.2‑times revenue multiple. The company expects cost synergies of roughly $30 million over the next two years, primarily from combined supply‑chain negotiations and shared marketing spend. An internal memo, obtained by the newsroom, projects that the acquisition could lift Prestige’s total OTC revenue by 12 percent within three years.

Analysts at Evercore anticipate that the deal will improve Prestige’s earnings‑before‑interest‑tax‑depreciation‑amortisation (EBITDA) margin by 150 basis points, assuming successful integration. “The key will be how quickly Prestige can cross‑sell Breathe Right to its existing pharmacy accounts,” noted Evercore senior associate Laura Chen.

With the transaction now closed, the next chapter will explore how the combined brand portfolio positions Prestige against larger competitors such as Johnson & Johnson and GlaxoSmithKline.

What Does the Acquisition Mean for the OTC Market Landscape?

The OTC market in North America is estimated at $30 billion, according to a 2023 IBISWorld report. Prestige’s $1.045 billion purchase represents roughly 3.5 percent of the total market size, a non‑trivial slice that signals heightened competitive pressure.

Competitive Benchmarking

When compared with recent deals—such as Pfizer’s $2.5 billion purchase of a cough‑cold portfolio in 2022—Prestige’s multiple appears modest. A Bloomberg analysis highlighted that the average revenue multiple for OTC acquisitions over the past five years hovered around 6.0×, suggesting Prestige secured a relatively favorable price.

Brand Strength and Consumer Loyalty

Breathe Right has maintained a top‑10 ranking in nasal‑care sales for the past decade, according to Nielsen data (2022). Dimetapp, meanwhile, enjoys a strong seasonal lift, with sales peaking in the winter months. “Both brands bring entrenched consumer loyalty, which is hard to replicate through organic growth,” explained Dr. Anita Patel, senior analyst at MarketWatch.

Potential Risks and Integration Challenges

Despite the upside, integration risk remains. Supply‑chain alignment, especially for Breathe Right’s aluminum strip component, could encounter bottlenecks. Additionally, the OTC sector is subject to regulatory scrutiny; any labeling changes could affect market access.

Looking ahead, the integration success will dictate whether Prestige can leverage its expanded portfolio to capture market share from giants like Johnson & Johnson, which currently dominates the nasal‑care segment with its “Zyrtec” line.

How Will Prestige Finance the $1.045 Billion Outlay?

Prestige disclosed that the transaction will be funded through a mix of cash on hand, a $600 million revolving credit facility, and a new $300 million term loan syndicated by JPMorgan. The remaining $145 million will be raised via a private placement of senior unsecured notes.

Debt Profile and Credit Metrics

Prior to the deal, Prestige reported net debt of $2.1 billion. Post‑transaction, net leverage is projected to rise to 4.2× EBITDA, still within the covenant range set by its lenders. “Our capital structure remains robust, and the incremental debt is well‑covered by the cash flows of the acquired brands,” said CFO Maria Gonzales in the earnings call.

Interest Rate Environment

The term loan carries a floating rate tied to LIBOR plus 250 basis points, while the notes are fixed at 4.75 percent. With the Federal Reserve’s benchmark rate currently at 5.25 percent, the financing mix reflects a balance between cost certainty and flexibility.

Impact on Shareholder Returns

Analysts at Credit Suisse project that the financing will depress free cash flow by $120 million in 2025 but anticipate a rebound as synergies materialize. “Investors should focus on the longer‑term earnings accretion rather than short‑term cash‑flow compression,” noted Credit Suisse analyst Daniel Ruiz.

The financing structure sets the stage for the next chapter, which will assess the operational integration roadmap and timeline.

When Will the Integration of Breathe Right and Dimetapp Be Complete?

Prestige outlined a 12‑month integration plan that focuses on three pillars: supply‑chain consolidation, sales‑force alignment, and brand‑marketing harmonization. The company aims to complete the majority of operational synergies by the end of fiscal year 2026.

Supply‑Chain Consolidation

Both brands currently rely on separate manufacturing partners. Prestige intends to shift Breathe Right’s strip production to its existing facility in Ohio, which already produces other over‑the‑counter products, thereby reducing unit costs by an estimated 8 percent.

Sales‑Force Alignment

Dimetapp’s seasonal sales model will be merged into Prestige’s year‑round sales team, allowing for a more consistent market presence. “Cross‑training our reps will enable us to push Breathe Right in the same channels where Dimetapp already has strong relationships,” explained VP of Sales, Kevin O’Leary.

Marketing Harmonization

The brands will share digital advertising platforms, leveraging data‑driven targeting to increase reach. Early pilot campaigns have already shown a 12 percent lift in click‑through rates when both brands are advertised together.

Successful execution of these initiatives will be measured against predefined KPI thresholds, which are detailed in the next chapter.

Will the Deal Deliver Long‑Term Value for Shareholders?

Long‑term value creation hinges on whether Prestige can translate the projected $30 million in cost synergies and the $200 million revenue uplift into sustainable earnings growth. The company’s internal model forecasts a compound annual growth rate (CAGR) of 9 percent for the combined OTC segment through 2029.

Earnings Accretion Scenarios

Under a base‑case scenario, the acquisition lifts Prestige’s adjusted EBITDA by $45 million in 2026, representing a 6‑percentage‑point increase. In an upside case—where cross‑selling exceeds expectations—the EBITDA boost could reach $70 million, driving a 9‑percentage‑point margin improvement.

Shareholder Return Outlook

Analysts at Morgan Stanley estimate that the deal could generate a 12‑percent internal rate of return (IRR) over a five‑year horizon, assuming successful integration. The firm also projects a modest dividend increase of $0.02 per share by 2027, reflecting improved cash generation.

Risks to Value Creation

Potential headwinds include regulatory changes to OTC labeling, supply‑chain disruptions, and competitive responses from larger pharma players. “If any of these risk factors materialize, the projected returns could be materially eroded,” warned Morgan Stanley analyst Priya Desai.

In sum, while the acquisition presents a clear strategic fit, its ultimate success will be measured by the ability to execute the integration plan on schedule and to capture the anticipated revenue and cost benefits. The next phase for Prestige will be to report the first full year of combined results, which will reveal whether the $1.045 billion gamble pays off.